May 27, 2025ESMO OpenOpen Access

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial

View Full Paper

Ask AI

Bookmark

Abstract

Durvalumab after sCRT was well tolerated and could be an alternative treatment strategy when cCRT is not feasible. Confirmatory randomized phase III data are awaited.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garassino et al. (2025) studied this question.

synapsesocial.com/papers/69d8cbf02c39562886ae2ccd https://doi.org/10.1016/j.esmoop.2025.105071

View Full Paper

Ask AI

Bookmark

Abstract

Durvalumab after sCRT was well tolerated and could be an alternative treatment strategy when cCRT is not feasible. Confirmatory randomized phase III data are awaited.

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial

Abstract

Discussion

Cite This Study

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading